Sign In

Jon Wigginton, MD

President, Research and Development Bright Peak Therapeutics/Strategic Advisor to Biotech/Experienced CMO-Oncology and Immuno-Oncology

Jon Wigginton, MD, currently serves as the President of Research and Development at Bright Peak Therapeutics, a position he has held since August 2022. His role involves overseeing all research and development functions, including discovery, manufacturing, clinical research, and regulatory affairs. He collaborates closely with the CEO and Executive Committee on corporate strategy and interfaces with investors and partners.13

Professional Background

Dr. Wigginton has over 25 years of experience in clinical oncology and drug development. Before joining Bright Peak Therapeutics, he was the Chief Medical Officer at MacroGenics, where he led clinical development programs. He also held significant roles at Bristol Myers Squibb, including Therapeutic Area Head for Immuno-Oncology.23 His early career included a notable tenure at the National Cancer Institute, where he was the Head of the Investigational Biologics Section.14

Education

Dr. Wigginton earned his M.D. from the University of Michigan, where he also completed his undergraduate studies in biology.23

Additional Roles

In addition to his work at Bright Peak, he is a member of the Board of Directors for Sutro Biopharma and has held various leadership positions in organizations such as the Society for Immunotherapy of Cancer (SITC).12

Dr. Wigginton's extensive experience positions him as a prominent figure in the field of cancer immunotherapy, particularly in developing novel cytokine-based therapeutics.34

Highlights

Aug 31 · linkedin

Not professional. No explanation required. GO BLUE!

Aug 2 · linkedin

Now we have another cell therapy approved for solid tumors. Adaptimmune receives FDA approval for cell therapy (afamitresgene autoleucel) for the treatment of MAGE-A4+ synovial cell sarcoma. Accelerated approval based 44 patient study with ORR=43% and a median DoR of 6 months. First engineered cell therapy for solid tumors, and now along with lifileucel TIL therapy from Iovance, the second cell therapy for solid tumors. We now have had 33 immuno-oncology drugs approved by the FDA, with 30 approved in the last ~10 years. #cancer #oncology #immunotherapy #immunooncology #cancerimmunotherapy #drugdevelopment

Related Questions

What are Jon Wigginton's key achievements at Bright Peak Therapeutics?
How did Jon Wigginton's role at Bristol-Myers Squibb influence his career?
What is the significance of Jon Wigginton's work at the National Cancer Institute?
How has Jon Wigginton's leadership impacted the development of cancer immunotherapy drugs?
What are the main projects Jon Wigginton is currently involved in at Bright Peak Therapeutics?
Jon Wigginton, MD
Jon Wigginton, MD, photo 1
Jon Wigginton, MD, photo 2
Add to my network

Location

Washington DC-Baltimore Area